Archived job profiles for health visiting roles - NHS Employers

ICE Health Service Corps focused on best patient outcomes The ICE Health Service Corps (IHSC) is the only entity in ICE with the responsibility of providing direct patient care. IHSC’s vision is to be the best health care delivery system in detention and correctional health care. IHSC’s mission is to provide the safe delivery of high-quality health care to those in ICE custody. IHSC is made up of a workforce of approximately 1,670 employees that includes U. S. Public Health Service (PHS) Commissioned Corps officers, federal civil servants, and contract health professionals. IHSC is committed to providing health care services to reduce global disease and support the safe apprehension, enforcement and removal of detained individuals involved in immigration proceedings. ICE Health Care SystemIn Fiscal Year (FY) 2023, IHSC provided direct care to more than 131,000 noncitizens housed at 19 designated facilities throughout the nation to include medical, dental, and mental health care, and public health services.

Children who eat more ultra-processed foods (UPFs) show stronger responses in the brain's reward network when viewing images of appetizing foods-and these brain responses are linked to increases in body fat one year later. The findings, just published in JAMA Network Open, suggest that the brain may become more sensitive to food cues when children consume more UPFs. UPFs are manufactured food products-such as breakfast cereals, packaged bread and instant soups-that are designed to be highly palatable, convenient and shelf-stable. They often contain artificial sweeteners, colors and other ingredients that people do not typically use when cooking at home. On average, U. S. children get about 67% of their daily calories from UPFs.

Hiroshima University researchers investigated the effects of hydrogen supplementation on sleep quality in healthy human volunteers. While hydrogen supplementation had no significant effect compared to a placebo, individuals in the hydrogen-supplementation group reporting better sleep quality were discovered to have a lower abundance of hydrogen producing bacteria in their gut microbiome. A Hiroshima University-led randomized, double-blind clinical trial found that hydrogen supplementation did not significantly improve sleep quality compared to a placebo; however, exploratory analyses suggest that differences in the abundance of hydrogen-producing gut bacteria may be associated with individual differences in sleep-related responses.

The World Health Organization (WHO) has announced the beginning of the first clinical trial of an Ebola vaccine in the outbreak that started in the Democratic Republic of Congo (DRC). WHO’s director-general, Tedros Adhanom Ghebreyesus, said in a social media post on Friday that participants in the trial were vaccinated with the Ervebo vaccine in Bunia, the capital of the DRC’s northeastern Ituri province, which is the epicentre of the Ebola outbreak. Recommended Stories list of 3 itemslist 1 of 3Kenya announces second Ebola death, says ‘no evidence’ of community spreadlist 2 of 3Nigeria’s first Ebola case matches DR Congo strain, health officials saylist 3 of 3WHO warns ‘more complex’ Ebola outbreak now present in 3 African countriesend of listErvebo, a vaccine approved for use against the more common Zaire strain of Ebola, will be put through a full-scale human trial to see if it offers any cross-protection against the Bundibugyo species of Ebola that is behind the epidemic. “This trial will help us understand whether any of the vaccine candidates designed for Bundibugyo virus work,” the WHO chief said on X.

Prostate cancer is the most common cancer in men—in 2013, it affected more than 1 million men across the world. The cancer does not behave the same way in every patient, and doctors have long faced a difficult balancing act between identifying patients who will benefit from more intensive treatment and those who may do just as well without it. Treating someone more aggressively than necessary is associated with increased side effects and poorer quality of life. At a major cancer conference in Madrid, a team from University College London unveiled the latest findings from their STAMPEDE clinical trial, which has shown that adding the hormone therapy abiraterone to the standard treatment for men with high-risk, localized prostate cancer could halve the risk of death from the disease and slow overall progression.